10/18/2024

Janusmed sex and gender

Janusmed sex and gender – carboplatin

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C! C!
C! C!

Carboplatin

Carboplatin

Class : C!

Show all info

Print

Contact us

  1. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.

  2. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.

  3. Socialstyrelsen. Cancer i siffror 2018. Socialstyrelsen [www]. [updated 2018-06-10, cited 2020-10-01].

  4. Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.

  5. Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187-96.

  6. Ferguson MK, Skosey C, Hoffman PC, Golomb HM. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990;8(8):1402-7.

  7. Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005;23(4):850-6.

  8. de Perrot M, Licker M, Bouchardy C, Usel M, Robert J, Spiliopoulos A. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg. 2000;119(1):21-6.

  9. Visbal AL, Williams BA, Nichols FC, Marks RS, Jett JR, Aubry MC et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004;78(1):209-15; discussion 215.

  10. Hsu LH, Chu NM, Liu CC, Tsai SY, You DL, Ko JS et al. Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor?. Lung Cancer. 2009;66(2):262-7.

  11. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ et al. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9(3):140-7.

  12. Beumer JH, Inker LA, Levey AS. Improving Carboplatin Dosing Based on Estimated GFR. Am J Kidney Dis. 2018;71(2):163-165.

  13. Carboplatin Accord (karboplatin). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2019-03-19, cited 2021-09-15]

  14. van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol. 1996;37(3):266-70.

  15. Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Cancer Chemother Pharmacol. 1998;42(4):307-12.

  16. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995;13(8):1860-70.

  17. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995;87(8):573-80.

  18. Rossi A, Chiodini P, Sun JM, O'Brien ME, von Plessen C, Barata F et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2014;15(11):1254-62.

  19. Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol. 2006;1(5):441-6.

  20. Yamamoto H, Sekine I, Yamada K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T. Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel. Oncology. 2008;75(3):169-74.

  21. Salama JK, Hodgson L, Pang H, Urbanic JJ, Blackstock AW, Schild SE et al. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. J Thorac Oncol. 2013;8(8):1043-9.

  22. Hayashi T, Shimokawa M, Matsuo K, Iihara H, Kawada K, Nakano T et al. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis. BMC Cancer. 2021;21(1):74.

  23. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]

  1. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.
  2. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.
  3. Socialstyrelsen. Cancer i siffror 2018. Socialstyrelsen [www]. [updated 2018-06-10, cited 2020-10-01].
  4. Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.
  5. Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187-96.
  6. Ferguson MK, Skosey C, Hoffman PC, Golomb HM. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990;8(8):1402-7.
  7. Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005;23(4):850-6.
  8. de Perrot M, Licker M, Bouchardy C, Usel M, Robert J, Spiliopoulos A. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg. 2000;119(1):21-6.
  9. Visbal AL, Williams BA, Nichols FC, Marks RS, Jett JR, Aubry MC et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004;78(1):209-15; discussion 215.
  10. Hsu LH, Chu NM, Liu CC, Tsai SY, You DL, Ko JS et al. Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor?. Lung Cancer. 2009;66(2):262-7.
  11. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ et al. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9(3):140-7.
  12. Beumer JH, Inker LA, Levey AS. Improving Carboplatin Dosing Based on Estimated GFR. Am J Kidney Dis. 2018;71(2):163-165.
  13. Carboplatin Accord (karboplatin). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2019-03-19, cited 2021-09-15]
  14. van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol. 1996;37(3):266-70.
  15. Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Cancer Chemother Pharmacol. 1998;42(4):307-12.
  16. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995;13(8):1860-70.
  17. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995;87(8):573-80.
  18. Rossi A, Chiodini P, Sun JM, O'Brien ME, von Plessen C, Barata F et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2014;15(11):1254-62.
  19. Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol. 2006;1(5):441-6.
  20. Yamamoto H, Sekine I, Yamada K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T. Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel. Oncology. 2008;75(3):169-74.
  21. Salama JK, Hodgson L, Pang H, Urbanic JJ, Blackstock AW, Schild SE et al. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. J Thorac Oncol. 2013;8(8):1043-9.
  22. Hayashi T, Shimokawa M, Matsuo K, Iihara H, Kawada K, Nakano T et al. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis. BMC Cancer. 2021;21(1):74.
  23. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]